title: Comparative speed of kill of sarolaner (Simparica and fluralaner (Bravecto) against induced infestations of Ctenocephalides felis on dogs.
abstract: BACKGROUND
  Fleas are the most common ectoparasite infesting dogs globally and cause direct discomfort, induce allergic reactions, and transmit pathogenic agents. Rapid speed of kill is an important characteristic for a parasiticide in order to alleviate the direct deleterious effects of fleas, reduce the impact of allergic responses, and break the flea life cycle. In this study, the speed of kill of a novel, orally administered isoxazoline parasiticide, sarolaner (Simparica), against fleas on dogs was evaluated and compared with fluralaner (Bravecto) over a 3-month period.
  
  
  METHODS
  Based on pretreatment flea counts, 24 dogs were randomly allocated to treatment with oral sarolaner at the label rate (2 to 4 mg/kg), once a month for 3 months, or oral fluralaner (25 to 50 mg/kg), once per label directions, or placebo. Dogs were combed and live fleas counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 14, 29, 44, 59, 74 and 90. Efficacy was determined at each time point relative to counts for placebo dogs.
  
  
  RESULTS
  There were no adverse reactions to treatment. Three monthly doses of sarolaner provided ≥97.6 % efficacy (based on arithmetic means) within 8 h of treatment or subsequent weekly re-infestations of fleas for 3 months. By 12 h, fleas were eradicated from all dogs (100 % efficacy). Significantly greater numbers of live fleas were recovered from fluralaner-treated dogs at 8 h on Days 74 and 90 (P ≤ 0.0043) when efficacy (based on arithmetic means) was only 80.7 and 72.6 %, respectively.
  
  
  CONCLUSIONS
  In this controlled laboratory evaluation, sarolaner had a significantly faster speed of kill against fleas than fluralaner at the end of its claimed treatment period. The rapid and consistent kill of fleas within 8 to 12 h after monthly oral doses of sarolaner indicates that this treatment will provide rapid and highly effective control of flea infestations, and suggests that it will provide relief for dogs suffering from flea allergy dermatitis, and should reduce the risk of flea-borne pathogen transmission.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI, 49007, USA. robert.six@zoetis.com.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Six
authors.affiliation: ClinVet International (pty) Ltd, Uitsigweg, Bainsvlei 9338, Bloemfontein, Republic of South Africa. julian.liebenberg@clinvet.com.
authors.forename: Julian
authors.initials: J
authors.lastname: Liebenberg
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI, 49007, USA. nicole.a.honsberger@zoetis.com.
authors.forename: Nicole A
authors.initials: NA
authors.lastname: Honsberger
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI, 49007, USA. sean.mahabir@zoetis.com.
authors.forename: Sean P
authors.initials: SP
authors.lastname: Mahabir
mesh_terms: D000284:Administration, Oral; D000818:Animals; D058251:Ctenocephalides / Q000187:drug effects* / Q000502:physiology*; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D058267:Flea Infestations / Q000188:drug therapy / Q000662:veterinary*; D007306:Insecticides / Q000008:administration & dosage*; D007555:Isoxazoles / Q000008:administration & dosage*; D059208:Parasite Load; D010919:Placebos / Q000008:administration & dosage; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007306:Insecticides; D007555:Isoxazoles; D010919:Placebos